Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Charles River Laboratories Announces Second-Quarter 2007 Results from Continuing Operations

Downloadable version.

  • Sales Increase 14.8% to $307 Million
  • GAAP EPS Increase 19.6% to $0.55
  • Non-GAAP EPS Increase 10.3% to $0.64
  • 2007 Sales Guidance Increased and EPS Guidance Narrowed to Upper End of Range
  • Increases Stock Repurchase Authorization by $100 Million

WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 7, 2007--Charles River Laboratories International, Inc. (NYSE: CRL) today reported second-quarter and year-to-date 2007 financial results. For the second quarter, net sales from continuing operations increased 14.8% to $307.4 million from $267.9 million in the second quarter of 2006. Pharmaceutical and biotechnology customers continued to demonstrate robust demand for research models and outsourced services, which drove the strong sales growth in both the Research Models and Services and Preclinical Services business segments. Foreign exchange contributed 2.1% to the net sales growth.

On a GAAP basis, net income from continuing operations for the second quarter of 2007 was $37.8 million, or $0.55 per diluted share, compared to $32.8 million, or $0.46 per diluted share, for the second quarter of 2006. The 19.6% increase in earnings per share resulted primarily from higher sales, as well as the benefit of cost savings initiatives implemented in 2006, a lower share count due to the Company's stock repurchase program, lower amortization of intangible assets and reduced net interest expense.

On a non-GAAP basis, net income from continuing operations was $43.8 million for the second quarter of 2007, compared to $41.6 million for the same period in 2006. Second-quarter diluted earnings per share on a non-GAAP basis were $0.64, an increase of 10.3% compared to $0.58 per share in the second quarter of 2006. Non-GAAP earnings per share in the second quarter of 2007 excluded $8.2 million of amortization of intangible assets and stock-based compensation related to acquisitions and a charge of $0.9 million related to the decision to accelerate the exit of the Company's Preclinical Services facility in Worcester, Massachusetts. The Company continues to anticipate completion of the transition to the new Shrewsbury, Massachusetts, facility by the end of 2007, and as a result, expects to record total related charges in 2007 of approximately $0.03 to $0.05. For the second quarter of 2006, non-GAAP results excluded $9.5 million of amortization of intangible assets and stock-based compensation related to acquisitions and a charge of $5.3 million related to cost-savings initiatives.

James C. Foster, Chairman, President and Chief Executive Officer, said, "We are extremely pleased with our second-quarter performance, which reflects strong demand across our broad portfolio of essential products and services. As a result of higher-than-expected first-half sales and our expectation for robust sales growth in the second half of the year, we are raising our sales guidance and narrowing our EPS guidance to the upper end of the range. In addition, we have increased our stock repurchase authorization from $300.00 million to $400.00 million."

The Company reports results from continuing operations, which exclude results of the Interventional and Surgical Services (ISS) business. The Company is in the process of closing that business and as a result, reports it as discontinued operations. Historical comparisons have been reclassified accordingly. Net income from discontinued operations was $0.1 million in the second quarter of 2007. Including discontinued operations, net income for the second quarter of 2007 was $38.0 million, or $0.55 per diluted share, compared to net income of $25.7 million, or $0.36 per diluted share, in the second quarter of 2006. Discontinued operations in 2006 included both ISS and the Phase II - IV clinical services business, which the Company sold in August 2006.

Research Models and Services (RMS)

Sales for the RMS segment were $143.8 million in the second quarter of 2007, an increase of 9.9% from $130.8 million in the second quarter of 2006. Sales benefited from strong demand for research models from large pharmaceutical and biotechnology customers in North America and Europe, increased demand for Transgenic Services, and higher sales of in vitro products.

In the second quarter of 2007, the RMS segment's GAAP operating margin increased to 31.5% compared to 29.1% in the second quarter of 2006. On a non-GAAP basis, which excluded charges of $0.4 million for acquisition-related amortization, the operating margin was 31.7%, compared to 30.9% for the same period in the prior year. The improvement was due primarily to higher sales.

Preclinical Services (PCS)

Second-quarter net sales for the PCS segment were $163.6 million, an increase of 19.4% from $137.0 million in the second quarter of 2006. Sales were driven by continuing strong demand for general and specialty toxicology services from pharmaceutical and biotechnology customers, and the addition on October 30, 2006, of the Northwest Kinetics Phase I clinical services business.

The PCS segment's GAAP operating margin improved to 16.8% from 16.4%. On a non-GAAP basis, which excludes $7.8 million of acquisition-related amortization and the $0.9 million charge for the accelerated exit from the Worcester facility, the second-quarter operating margin declined to 22.0% from 25.4% in the second quarter of 2006. All of the Company's preclinical toxicology facilities reported improved profitability, with the exception of Massachusetts. As expected, the higher operating costs associated with the Massachusetts facility transition offset the gains.

Six-Month Results

For the first six months of 2007, net sales from continuing operations increased by 14.7% to $598.6 million, from $522.0 million in the same period in 2006. Foreign exchange contributed approximately 2.4% to the sales growth rate.

On a GAAP basis, net income from continuing operations was $75.1 million, or $1.10 per diluted share, for the first half of 2007, compared to $61.3 million, or $0.84 per diluted share, for the same period in 2006.

On a non-GAAP basis, net income from continuing operations for the first six months of 2007 was $87.0 million, or $1.28 per diluted share, compared to $76.4 million, or $1.05 per diluted share, for the same period in 2006. For the first six months of 2007, non-GAAP net income excluded $16.1 million of amortization and stock-based compensation costs associated with acquisitions, and $1.7 million related to the decision to accelerate the exit of the Company's Preclinical Services facility in Worcester, Massachusetts. Non-GAAP net income for the first half of 2006 excluded acquisition-related charges of $18.9 million and charges of $5.3 million related to cost-savings initiatives.

Including a loss of $0.3 million from discontinued operations, net income for the first six months of 2007 was $74.7 million, or $1.10 per diluted share, compared to a net loss of $74.4 million, or $1.02 per diluted share, for the same period in 2006. Results for the prior year included the $129.2 million goodwill impairment recorded in the first quarter of 2006 related to the sale of the Clinical Phase II - IV business.

Research Models and Services (RMS)

For the first six months of 2007, RMS net sales were $286.9 million, an increase of 10.4% from the first-half 2006 net sales of $259.8 million. The RMS segment's GAAP operating margin was 32.2% in the first half of 2007, compared to 30.2% for the year-ago period. On a non-GAAP basis, which excluded $0.7 million of amortization of intangible assets related to acquisitions, the operating margin was 32.4% compared to 31.2% in the first six months of 2006.

Preclinical Services (PCS)

For the first six months of 2007, PCS net sales were $311.8 million, an increase of 18.9% over first-half 2006 net sales of $262.2 million. On a GAAP basis, the PCS segment operating margin was 16.3% in the first half of 2007, compared to 13.9% in the year-ago period. On a non-GAAP basis, the operating margin was 21.7% in the first half of 2007 compared to 22.0% for the same period in 2006.

2007 Guidance

Based on strong demand for its products and services, the Company is increasing its sales guidance and narrowing the GAAP and non-GAAP earnings per share ranges to the upper end. The revised forward-looking guidance, shown in the table below, is based on current foreign exchange rates.

2007 GUIDANCE (from continuing
 operations)                               REVISED          PRIOR
----------------------------------------------------------------------
Net sales growth (in %)                   12% - 14%       9% - 12%
Sales ($ in millions)                  $1,185 - $1,205 $1,160 - $1,190
GAAP EPS estimate                       $2.15 - $2.21   $2.11 - $2.21
Acquisition-related amortization            $0.32           $0.32
Charge to exit Worcester facility and
 gain on sale of building, net          $0.01 - $0.03   $0.01 - $0.03
                                       -------------------------------
Non-GAAP EPS estimate                   $2.47 - $2.53   $2.43 - $2.53
----------------------------------------------------------------------

Board Increases Stock Repurchase Authorization

Charles River's Board of Directors has increased the existing authorization for the repurchase of Charles River common stock to $400.0 million from $300.0 million. The stock purchases will be made from time to time on the open market, through block trades or otherwise in compliance with Rule 10b-18 of the federal securities laws. Depending on market conditions and other factors, these repurchases may be commenced or suspended at any time or from time to time without prior notice. Funds for the repurchases are expected to come from cash on hand or cash generated by operations.

As of August 1, 2007, the Company had repurchased 6.7 million shares of common stock at a total cost of approximately $278.0 million, leaving a balance of approximately $122.0 million under the $400.00 million stock repurchase authorization. There are currently no specific plans for the shares that have been or may be purchased under the program.

As of August 1, 2007, Charles River had approximately 67.9 million shares of common stock outstanding.

Webcast

Charles River Laboratories has scheduled a live webcast on Wednesday, August 8, at 8:30 a.m. ET to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliations to comparable GAAP measures on the website.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, such as non-GAAP earnings per diluted share from continuing operations, which exclude amortization of intangible assets and other charges related to our acquisitions, impairments due to our accelerated exit from our Worcester Preclinical Services facility, and the potential gain on the sale of real estate in Scotland. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. There are limitations in using non-GAAP financial measures, as they are not prepared in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities, such as business acquisitions, happen infrequently and the underlying costs associated with such activities do not recur. Non-GAAP results also allow investors to compare the Company's operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in the text of this press release, and can also be found on the Company's website at ir.criver.com.

Caution Concerning Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding our projected 2007 earnings; the future demand for drug discovery and development products and services, including the outsourcing of these services; the impact of specific actions intended to improve overall operating efficiencies and profitability; expectations regarding stock repurchases; the timing of the opening of new and expanded facilities; the potential sale of real estate in Scotland; future cost reduction activities by our customers; and Charles River's future performance as delineated in our forward-looking guidance, and particularly our expectations with respect to sales growth. Forward-looking statements are based on Charles River's current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: a decrease in research and development spending, a decrease in the level of outsourced services, or other cost reduction actions by our customers; the ability to convert backlog to sales; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 27, 2007, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law.

About Charles River Laboratories

Charles River Laboratories based in Wilmington, Massachusetts, partners with global pharmaceutical and biotechnology companies, government agencies and leading academic institutions to advance the drug discovery and development process, bringing drugs to market faster and more efficiently. Charles River's 8,000 employees serve clients worldwide. For more information on Charles River, visit our website at www.criver.com.

            CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
       CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
          (dollars in thousands, except for per share data)

                      Three Months Ended         Six Months Ended
                   ------------------------- -------------------------
                    June 30,                  June 30,
                       2007     July 1, 2006     2007     July 1, 2006

Total net sales    $   307,435  $   267,859  $   598,634  $   522,000
Cost of products
 sold and services
 provided              186,479      160,749      362,105      319,385
                   ------------ ------------ ------------ ------------
Gross margin           120,956      107,110      236,529      202,615
Selling, general
 and
 administrative         56,092       50,031      109,109       92,765
Amortization of
 intangibles             8,139        9,377       15,994       18,452
                   ------------ ------------ ------------ ------------
Operating income        56,725       47,702      111,426       91,398
Interest income
 (expense)              (2,595)      (3,661)      (4,654)      (6,677)
Other income
 (expense)              (1,069)        (736)        (920)        (688)
                   ------------ ------------ ------------ ------------
Income before
 income taxes and
 minority
 interests              53,061       43,305      105,852       84,033
Provision for
 income taxes           15,101        9,870       30,411       21,681
                   ------------ ------------ ------------ ------------
Income before
 minority
 interests              37,960       33,435       75,441       62,352
Minority interests        (119)        (654)        (373)      (1,056)
                   ------------ ------------ ------------ ------------
Income from
 continuing
 operations             37,841       32,781       75,068       61,296
Income (loss) from
 discontinued
 businesses, net
 of tax                    115       (7,032)        (349)    (135,662)
                   ------------ ------------ ------------ ------------
Net income (loss)  $    37,956  $    25,749  $    74,719  $   (74,366)
                   ============ ============ ============ ============

Earnings (loss)
 per common share
  Basic:
  Continuing
   operations      $      0.57  $      0.46  $      1.13  $      0.86
  Discontinued
   operations      $         -  $     (0.10) $     (0.01) $     (1.89)
  Net income       $      0.57  $      0.36  $      1.12  $     (1.04)
  Diluted:
  Continuing
   operations      $      0.55  $      0.46  $      1.10  $      0.84
  Discontinued
   operations      $         -  $     (0.10) $     (0.01) $     (1.86)
  Net income       $      0.55  $      0.36  $      1.10  $     (1.02)

Weighted average number of common shares outstanding
  Basic             66,830,155   70,851,430   66,587,863   71,615,867
  Diluted           68,517,657   71,835,166   67,971,898   72,798,832
            CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
          CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
                        (dollars in thousands)



                                              June 30,    December 30,
                                                 2007         2006
Assets
Current assets
   Cash and cash equivalents                 $    162,050 $    175,380
   Trade receivables, net                         228,622      202,658
   Inventories                                     77,169       72,362
   Other current assets                            58,583       44,363
   Current assets of discontinued businesses        1,123        6,330
                                             ------------ ------------
      Total current assets                        527,547      501,093
Property, plant and equipment, net                622,492      534,745
Goodwill, net                                   1,119,350    1,119,309
Other intangibles, net                            158,442      160,204
Deferred tax asset                                 96,121      107,498
Other assets                                      135,910      133,944
Long-term assets of discontinued businesses         4,217          751
                                             ------------ ------------
      Total assets                           $  2,664,079 $  2,557,544
                                             ============ ============

Liabilities and Shareholders' Equity
   Current liabilities
   Current portion of long-term debt         $     24,098 $     24,977
   Accounts payable                                35,707       28,223
   Accrued compensation                            42,804       41,651
   Deferred income                                 94,963       93,197
   Accrued liabilities                             53,976       41,991
   Other current liabilities                       18,017       25,625
   Current liabilities of discontinued
    businesses                                        116        3,667
                                             ------------ ------------
      Total current liabilities                   269,681      259,331
Long-term debt                                    511,816      547,084
Other long-term liabilities                       149,294      146,695
                                             ------------ ------------
      Total liabilities                           930,791      953,110
                                             ------------ ------------
Minority interests                                  3,420        9,223
Total shareholders' equity                      1,729,868    1,595,211
                                             ------------ ------------
Total liabilities and shareholders' equity   $  2,664,079 $  2,557,544
                                             ============ ============
            CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
          SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)
                        (dollars in thousands)

                               Three Months Ended   Six Months Ended
                               ------------------- -------------------
                               June 30,  July 1,   June 30,  July 1,
                                  2007      2006      2007      2006
Research Models and Services
 Net sales                     $143,803  $130,816  $286,871  $259,788
 Gross margin                    63,109    55,478   126,763   111,344
 Gross margin as a % of net
  sales                            43.9%     42.4%     44.2%     42.9%
 Operating income                45,268    38,003    92,289    78,479
 Operating income as a % of
  net sales                        31.5%     29.1%     32.2%     30.2%
 Depreciation and amortization    5,663     5,237    11,232    10,272
 Capital expenditures            10,688     4,783    17,772     8,349

Preclinical Services
 Net sales                     $163,632  $137,043  $311,763  $262,212
 Gross margin                    57,847    51,632   109,766    91,271
 Gross margin as a % of net
  sales                            35.4%     37.7%     35.2%     34.8%
 Operating income                27,426    22,530    50,870    36,318
 Operating income as a % of
  net sales                        16.8%     16.4%     16.3%     13.9%
 Depreciation and amortization   15,569    15,288    29,913    29,913
 Capital expenditures            38,724    12,620    69,564    48,441


Unallocated Corporate Overhead $(15,969) $(12,831) $(31,733) $(23,399)


Total
 Net sales                     $307,435  $267,859  $598,634  $522,000
 Gross margin                   120,956   107,110   236,529   202,615
 Gross margin as a % of net
  sales                            39.3%     40.0%     39.5%     38.8%
 Operating income (loss)         56,725    47,702   111,426    91,398
 Operating income as a % of
  net sales                        18.5%     17.8%     18.6%     17.5%
 Depreciation and amortization   21,232    20,525    41,145    40,185
 Capital expenditures            49,412    17,403    87,336    56,790
            CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
                  RECONCILIATION OF GAAP TO NON-GAAP
          SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)
                        (dollars in thousands)

                               Three Months Ended   Six Months Ended
                               ------------------- -------------------
                               June 30,  July 1,   June 30,  July 1,
                                  2007      2006      2007      2006
Research Models and Services
 Net sales                     $143,803  $130,816  $286,871  $259,788
 Operating income                45,268    38,003    92,289    78,479
 Operating income as a % of
  net sales                        31.5%     29.1%     32.2%     30.2%
 Add back:
   Amortization related to
    acquisitions                    371        99       745       179
   Impairment and other
    charges                           -     2,334         -     2,334
                               --------- --------- --------- ---------
 Operating income, excluding
  specified charges (Non-GAAP) $ 45,639  $ 40,436  $ 93,034  $ 80,992
 Non-GAAP operating income as
  a % of net sales                 31.7%     30.9%     32.4%     31.2%

Preclinical Services
 Net sales                     $163,632  $137,043  $311,763  $262,212
 Operating income                27,426    22,530    50,870    36,318
 Operating income as a % of
  net sales                        16.8%     16.4%     16.3%     13.9%
 Add back:
   Amortization related to
    acquisitions                  7,768     9,278    15,249    18,273
   Impairment and other
    charges                         863     2,966     1,682     2,966
                               --------- --------- --------- ---------
 Operating income, excluding
  specified charges (Non-GAAP) $ 36,057  $ 34,774  $ 67,801  $ 57,557
 Non-GAAP operating income as
  a % of net sales                 22.0%     25.4%     21.7%     22.0%


Unallocated Corporate Overhead $(15,969) $(12,831) $(31,733) $(23,399)
 Add back:
   Stock-based compensation
    related to Inveresk
    acquisition                      18       117        88       402
                               --------- --------- --------- ---------
 Unallocated corporate
  overhead, excluding
  specified charges (Non-GAAP) $(15,951) $(12,714) $(31,645) $(22,997)


Total
 Net sales                     $307,435  $267,859  $598,634  $522,000
 Operating income                56,725    47,702   111,426    91,398
 Operating income as a % of
  net sales                        18.5%     17.8%     18.6%     17.5%
 Add back:
   Amortization related to
    acquisition                   8,139     9,377    15,994    18,452
   Impairment and other
    charges                         863     5,300     1,682     5,300
 Stock-based compensation
  related to Inveresk
  acquisition                        18       117        88       402
                               --------- --------- --------- ---------
 Operating income, excluding
  specified charges (Non-GAAP) $ 65,745  $ 62,496  $129,190  $115,552
 Non-GAAP operating income as
  a % of net sales                 21.4%     23.3%     21.6%     22.1%


Charles River management believes that supplementary non-GAAP
 financial measures provide useful information to allow investors to
 gain a meaningful understanding of our core operating results and
 future prospects, without the effect of one-time charges, consistent
 with the manner in which management measures and forecasts the
 Company's performance. The supplementary non-GAAP financial measures
 included are not meant to be considered superior to, or a substitute
 for results of operations prepared in accordance with GAAP. The
 Company intends to continue to assess the potential value of
 reporting non-GAAP results consistent with applicable rules and
 regulations.
            CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
         RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS
          (dollars in thousands, except for per share data)


                      Three Months Ended         Six Months Ended
                   ------------------------- -------------------------
                    June 30,                  June 30,
                       2007     July 1, 2006     2007     July 1, 2006

Net income (loss)  $    37,956  $    25,749  $    74,719  $   (74,366)
Less: Discontinued
 operations               (115)       7,032          349      135,662
                   ------------ ------------ ------------ ------------
Net income from
 continuing
 operations             37,841       32,781       75,068       61,296
Add back:
  Amortization
   related to
   acquisitions          8,139        9,377       15,994       18,452
  Stock-based
   compensation
   related to
   Inveresk
   acquisition              18          117           88          402
  Impairment and
   other charges           863        5,300        1,682        5,300
  Tax effect            (3,061)      (5,995)      (5,845)      (9,061)
                   ------------ ------------ ------------ ------------
Net income from
 continuing
 operations,
 excluding
 specified charges
 (Non-GAAP)        $    43,800  $    41,580  $    86,987  $    76,389
                   ============ ============ ============ ============


Weighted average
 shares
 outstanding -
 Basic              66,830,155   70,851,430   66,587,863   71,615,867
Effect of dilutive
 securities:
  2.25% senior
   convertible
   debentures          203,034            -            -            -
  Stock options
   and
   contingently
   issued
   restricted
   stock             1,350,004      851,925    1,250,385    1,043,535
  Warrants             134,464      131,811      133,650      139,430
                   ------------ ------------ ------------ ------------
Weighted average
 shares
 outstanding -
 Diluted            68,517,657   71,835,166   67,971,898   72,798,832
                   ============ ============ ============ ============

Basic earnings
 (loss) per share  $      0.57  $      0.36  $      1.12  $     (1.04)
Diluted earnings
 (loss) per share  $      0.55  $      0.36  $      1.10  $     (1.02)

Basic earnings per
 share, excluding
 specified charges
 (Non-GAAP)        $      0.66  $      0.59  $      1.31  $      1.07
Diluted earnings
 per share,
 excluding
 specified charges
 (Non-GAAP)        $      0.64  $      0.58  $      1.28  $      1.05



Charles River management believes that supplementary non-GAAP
 financial measures provide useful information to allow investors to
 gain a meaningful understanding of our core operating results and
 future prospects, without the effect of one-time charges, consistent
 with the manner in which management measures and forecasts the
 Company's performance. The supplementary non-GAAP financial measures
 included are not meant to be considered superior to, or a substitute
 for results of operations prepared in accordance with GAAP. The
 Company intends to continue to assess the potential value of
 reporting non-GAAP results consistent with applicable rules and
 regulations.

CONTACT: Charles River Laboratories International, Inc.
Investor Contact:
Susan E. Hardy, 781-262-7616
Corporate Vice President, Investor Relations
or
Media Contact:
Amy Cianciaruso, 978-658-6000 Ext. 1878
Associate Director, Public Relations

SOURCE: Charles River Laboratories International, Inc.

Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)